Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hong‐Fei Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-6076-4295; OpenAlex author ID A5056034058. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2022: 5 papers · 2023: 4 papers · 2024: 6 papers · 2025: 9 papers · 2026: 1 paper

Papers 25

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenoc… Co-author DOI 10.1002/advs.202511726↗
  3. CT-based machine learning radiomics predicts Ki-67 expression level and its relationship with overall survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-025-04798-y↗
  4. LINC00431 modulates KRAS and p53 stability to drive pancreatic cancer progression under hypoxia Co-author DOI 10.1016/j.gendis.2025.101696↗
  5. ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Co-author DOI 10.1016/j.tranon.2024.102261↗
  6. A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy. Co-author DOI 10.1039/d4tb02206h↗
  7. Predictors for low rates of surgical resection in elderly patients with resectable pancreatic ductal adenocarcinoma: a retrospective case-control study. Co-author DOI 10.1097/js9.0000000000001957↗
  8. An in-vivo pilot study of probe-based confocal laser endomicroscopy for detecting of pancreatic ductal adenocarcinoma intraoperatively. Co-author DOI 10.1097/js9.0000000000003754↗
  9. CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis. Co-author DOI 10.1186/s13046-025-03295-w↗
  10. TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis. Co-author DOI 10.7150/ijbs.104598↗
  11. Schwann cells in pancreatic cancer: Unraveling their multifaceted roles in tumorigenesis and neural interactions. First author DOI 10.1016/j.canlet.2024.216689↗
  12. Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospective analysis. First author DOI 10.1016/j.canlet.2024.217213↗
  13. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  14. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Co-author DOI 10.1016/j.gene.2024.148735↗
  15. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  16. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  17. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  18. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Co-author DOI 10.1007/s13402-022-00741-1↗
  19. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic … First author DOI 10.1007/s13402-023-00824-7↗
  20. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
  21. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  22. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.05.047↗
  23. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  24. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Co-author DOI 10.3389/fimmu.2022.983116↗
  25. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. First author DOI 10.3390/ph15111336↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 12 shared papers, 2022–2025 · strength 2.02
  2. Yu-Heng Zhu · 10 shared papers, 2022–2026 · strength 1.89
  3. Chongyi Jiang · 7 shared papers, 2024–2025 · strength 1.75
  4. Yan‐Miao Huo · 10 shared papers, 2022–2025 · strength 1.69
  5. Jia-Hao Zheng · 10 shared papers, 2022–2024 · strength 1.67
  6. Chunjing Li · 6 shared papers, 2024–2025 · strength 1.47
  7. Qin-Yuan Jia · 8 shared papers, 2022–2025 · strength 1.43
  8. Shu‐Heng Jiang · 7 shared papers, 2022–2026 · strength 1.27
  9. Zong‐Hao Duan · 7 shared papers, 2022–2025 · strength 1.27
  10. Minwei Yang · 7 shared papers, 2022–2025 · strength 1.20
  11. Li-Peng Hu · 6 shared papers, 2022–2026 · strength 1.07
  12. Zhiwei Cai · 4 shared papers, 2024–2025 · strength 0.99
  13. Dejun Liu · 6 shared papers, 2022–2024 · strength 0.94
  14. Jian‐Yu Yang · 5 shared papers, 2022–2024 · strength 0.73
  15. Rong Hua · 4 shared papers, 2022–2024 · strength 0.62
  16. Rong Hua · 3 shared papers, 2024–2026 · strength 0.60
  17. Jian Yang · 4 shared papers, 2022–2024 · strength 0.60
  18. Xueliang Fu · 4 shared papers, 2022–2024 · strength 0.59
  19. Xiaomei Yang · 3 shared papers, 2023–2026 · strength 0.58
  20. Yifan Yin · 3 shared papers, 2024 · strength 0.56
  21. Wei Liu · 3 shared papers, 2024 · strength 0.54
  22. Jia-Hao Chen · 2 shared papers, 2025 · strength 0.53
  23. Ruizhe He · 3 shared papers, 2022–2023 · strength 0.47
  24. Luju Jiang · 2 shared papers, 2025–2026 · strength 0.41
  25. Xueli Zhang · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.